Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | -92.05% |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 2.26% |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 65.24% |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | -636.10% |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -69.49% |
| 10 | Bristol Myers Squibb | 188.27 Mn | -10.88 Bn | 9.25 Bn | 151.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 151.69% |
| Mar 31, 2026 | 8.44% |
| Dec 31, 2025 | 1,324.03% |
| Sep 30, 2025 | 79.95% |
| Jun 30, 2025 | -22.34% |
| Mar 31, 2025 | 120.59% |
| Dec 31, 2024 | -95.60% |
| Sep 30, 2024 | -36.28% |
| Jun 30, 2024 | -16.28% |
| Mar 31, 2024 | -645.01% |
| Dec 31, 2023 | -10.42% |
| Sep 30, 2023 | 24.72% |
| Jun 30, 2023 | 48.12% |
| Mar 31, 2023 | 80.65% |
| Dec 31, 2022 | -10.98% |
| Sep 30, 2022 | 7.79% |
| Jun 30, 2022 | 40.62% |
| Mar 31, 2022 | -34.11% |
| Dec 31, 2021 | 124.05% |
| Sep 30, 2021 | -15.94% |